DOCSLIB.ORG

Antiviral Research and Development Against Dengue Virus

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antiviral Research and Development Against Dengue Virus Antiviral Research and Development Against Dengue Virus Bruno Canard, PhD. [email protected] 1 Table of Contents Part 1. Antivirals 3 A short historical view on antiviral research and therapies 3 Lessons learned from recent viral diseases and pandemies 3 The methods used to discover antivirals 4 Infected cell assays 5 Knowledge-based methods 5 The source of anti-infectious molecules 6 Why has natural product screening been neglected in antiviral research ? 8 Challenges associated with natural products in antiviral research 8 What is a validated antiviral target ? 9 Animal models 9 Patient cohorts and clinical trials 10 Frequent arguments about antiviral therapy feasibility 10 The introduction of dengue as a druggable disease 11 Diagnostics, and what does it tells us for antiviral therapy ? 11 Current treatment 11 Part 2. Dengue 13 Preamble 13 The Dengue Virus 13 The DENV targets for antiviral research 13 Overview of genome organisation 14 Overview of the DV particle and DV proteins as targets for drugs 14 The structural proteins 14 The Non-Structural proteins 15 RNA structures 17 The dengue validated targets 17 The cellular targets for antiviral research against dengue 18 siRNAs as tools and/or therapeutic agents 19 Response modifiers 20 Monoclonal antibodies 21 Mechanical devices 21 Part 3. Academic and academy-associated research centers 22 Part 4. The current industrial network of AV discovery 31 Part 5. Mapping the dengue drug design effort and needs 38 Annex 1. References 42 Annex 2. Patents 43 2 Part 1. Antivirals A short historical view on antiviral research and therapies The first significant successes of anti-infectious disease treatments originated from the discovery and use of antibiotics. The discovery of many viruses preceded largely the discovery of the first antiviral molecule, which occurred at least 40 years after that of penicillin in 1928. The first documented description of an antiviral molecule, that of 5-iodo-2'-desoxyuridine, occurred in 1959. It was discovered active against Herpes ophthalmologic infections and followed by a series of related active molecules. The fight against herpes was the perhaps the earliest and most significant driving force of antiviral research. Herpes was the only significant viral disease for which all technical elements and systems required to develop an antiviral molecule first became available (i.e., in vitro infected cell systems, animal models, chronically infected patients,…). The antiviral drug field came of age in the next decades with the first antiviral molecule finding its way to the clinic: Gertrude B. Elion discovered acyclovir(2) a scientific breakthrough for which she was later awarded the Nobel prize in 1988. The subsequent emergence of AIDS in 1981, and the following pandemics drastically changed the field of antiviral research, allowing the widening of concepts, technical developments, rules, and business. Lessons learned from recent viral diseases and pandemies HIV and HCV: chronic invaders The most important lesson comes from the following great achievement: it is possible to control a chronic infection of a very sophisticated virus, such as HIV, that hides inside the chromosomes of the infected cell. Although the victory is not total yet, it has profoundly changed the fate of the pandemic victims, at least in western countries. After being inspired by other research fields, anti-HIV research has “infected” other field of antiviral research and will continue to do so. Remarkably, after the identification of HIV, the control of HIV through antiretrovirals originated from a collective effort on a wide variety of scientific and medical fields, including efficient transfer from academia to the corporate world. More recently, hepatitis C virus (HCV) research is now boosting the antiviral chemotherapy field. Viral polymerases and proteases are targets par excellence, validated by the use of inhibitors against HIV reverse transcriptase and protease, hepatitis B polymerase, and herpes virus polymerase. Anti-HCV protease and polymerase inhibitors are in various stages of clinical trials. Novel targets and cognate inhIbitors are adding to the list, such as the HIV integrase, and the HCV NS5A. HCV (genus Hepacivirus) and DENV (genus Flavivirus) belong to the same viral family Flaviviridae sharing similar genome organization and replication strategies. Initially, research conducted on dengue virus (DENV) was the actual starting and inspiration point for HCV research, when it became known 3 that HCV had a flavivirus-like genome. Presently and conversely, knowledge and strategies gained from the successful drug discovery and design process against HCV can now be translated back to the DENV research field. SARS and Influenza (H5N1 and H1N1): “hit and run” viruses The SARS pandemic was due to a novel coronavirus which emerged in 2003 from China. The virus took the world by surprise as coronaviruses were not known to cause life threatening pathologies. Coronaviruses were clearly neglected viruses from the scientific and the medical/veterinary point-of- view. The pandemic revealed blatantly our unpreparedness to such a problem: point-of-care in hospitals crowded with contagious patients, high toll for clinicians, tracing secondary contacts of taxi drivers and plane passengers, etc…The pessimistic say that nowadays viruses travel around the world in 3 days. The optimistic say that social networks and cell phones make information travel much faster. Perhaps the true challenge is elsewhere: making people believe and adhere to an “official” information, as exemplified with the recent H1N1 crisis and the unsuccessful vaccination campaign. In any case, this crisis has been the best advocate for antivirals as a complementary strategy to prEvention and vaccination. In the case of influenza, the size of the market has been the main booster of anti-influenza drug development. This includes the availability of patients for clinical trials, and the fact that a potential devastating pandemic would undoubtedly provoke stockpiling of antivirals in the time-window into which an appropriate vaccine would available. Advice to stockpile anti-influenza drugs has been recurrently advertised, mostly after 1995 when the 1918 spanish influenza strain genome was published(8). well before the H5N1 and the H1N1 fear hit the world. These two viruses do not produce chronic infections. These types of virus produce an infection (unnoticed, mild, or acute) which resolves with virus clearance. This transient nature of the infection has long been a problem to design an efficient therapeutic answer. Indeed, there are too many unpredictable parameters to build a drug-design program based on traditional planning and funding approaches. The two biggest problems are that it is impossible to evaluate precisely the market (and invest accordingly), and that there is an unpredictable number of patients available for clinical trials. The instructive aspect of these pandemics, however, is that they greatly contributed to re-shape antiviral research at large (how can we anticipate? how money is going to be invested? ). These recent crises have shaped considerably the grand public opinion towards the necessity to have broad- spectrum anti-influenza drugs ready. The methods used to discover antivirals The original method of discovery of antivirals was partially a knowledge-based method, centered around nucleobases and nucleosides (eg., uridine derivatives mentioned above against Herpes), known to be used by viruses for their replication. The advent of AIDS and the discovery of non-nucleoside 4 reverse transcriptase inhibitors opened the era of large-scale screening, which is entirely a trial-and- error procedure, not based on previous knowledge. Millions of compounds are tested as fast as possible (using high throughput screening (HTS) techniques), and only those showing activity are selected. Infected cell assays In both cases (Herpes and AIDS), infected cell cultures provided the antiviral read out, before purified targets were available and could be used. In these assays, compounds are tested individually to see if they either cure an infected cell, or protect it from infection, pathogenic effects. The process is simple, and relies on a cell culture system able to support virus growth. Not surprisingly, the discovery of antivirals parallels the establishment of a robust infected cell based assay. When this was difficult or even not possible (eg., HCV), the use of sub-genomic replicons or surrogate viruses has nevertheless allowed drug discovery and design. There are now a wide variety of assay systems specific for each virus. Robust dengue infected cell assays are available, highly efficient in terms of characterizing the potency of a drug candidate. One significant disadvantage is the cost associated with cell culture reagents and facilities, especially in low income countries. However, this method has an impressive record of success compared to other methods. Knowledge-based methods The general trend is to reduce this trial-and-error approach and inject knowledge as much as possible in the selection process so as to reduce costs and increase efficiency. Computer-aided structure activity relationship (SAR) studies facilitate a responsive and efficient management of research results and programs. Drug-resistance must be considered as part of the drug- design process, as drug resistance mechanisms are being increasingly characterized and drug combinations optimized, in order to avoid or delay resistance.
Load more

Recommended publications
  • Highlights of Prescribing Information
    HIGHLIGHTS OF PRESCRIBING INFORMATION --------------------------WARNINGS AND PRECAUTIONS--------------------­ These highlights do not include all the information needed to use • New onset or worsening renal impairment: Can include acute VIREAD safely and effectively. See full prescribing information renal failure and Fanconi syndrome. Assess creatinine clearance for VIREAD. (CrCl) before initiating treatment with VIREAD. Monitor CrCl and ® serum phosphorus in patients at risk. Avoid administering VIREAD (tenofovir disoproxil fumarate) tablets, for oral use VIREAD with concurrent or recent use of nephrotoxic drugs. (5.3) VIREAD® (tenofovir disoproxil fumarate) powder, for oral use • Coadministration with Other Products: Do not use with other Initial U.S. Approval: 2001 tenofovir-containing products (e.g., ATRIPLA, COMPLERA, and TRUVADA). Do not administer in combination with HEPSERA. WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH (5.4) STEATOSIS and POST TREATMENT EXACERBATION OF HEPATITIS • HIV testing: HIV antibody testing should be offered to all HBV- infected patients before initiating therapy with VIREAD. VIREAD See full prescribing information for complete boxed warning. should only be used as part of an appropriate antiretroviral • Lactic acidosis and severe hepatomegaly with steatosis, combination regimen in HIV-infected patients with or without HBV including fatal cases, have been reported with the use of coinfection. (5.5) nucleoside analogs, including VIREAD. (5.1) • Decreases in bone mineral density (BMD): Consider assessment • Severe acute exacerbations of hepatitis have been reported of BMD in patients with a history of pathologic fracture or other in HBV-infected patients who have discontinued anti- risk factors for osteoporosis or bone loss. (5.6) hepatitis B therapy, including VIREAD. Hepatic function • Redistribution/accumulation of body fat: Observed in HIV-infected should be monitored closely in these patients.
    [Show full text]
  • COVID-19) Pandemic on National Antimicrobial Consumption in Jordan
    antibiotics Article An Assessment of the Impact of Coronavirus Disease (COVID-19) Pandemic on National Antimicrobial Consumption in Jordan Sayer Al-Azzam 1, Nizar Mahmoud Mhaidat 1, Hayaa A. Banat 2, Mohammad Alfaour 2, Dana Samih Ahmad 2, Arno Muller 3, Adi Al-Nuseirat 4 , Elizabeth A. Lattyak 5, Barbara R. Conway 6,7 and Mamoon A. Aldeyab 6,* 1 Clinical Pharmacy Department, Jordan University of Science and Technology, Irbid 22110, Jordan; [email protected] (S.A.-A.); [email protected] (N.M.M.) 2 Jordan Food and Drug Administration (JFDA), Amman 11181, Jordan; [email protected] (H.A.B.); [email protected] (M.A.); [email protected] (D.S.A.) 3 Antimicrobial Resistance Division, World Health Organization, Avenue Appia 20, 1211 Geneva, Switzerland; [email protected] 4 World Health Organization Regional Office for the Eastern Mediterranean, Cairo 11371, Egypt; [email protected] 5 Scientific Computing Associates Corp., River Forest, IL 60305, USA; [email protected] 6 Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield HD1 3DH, UK; [email protected] 7 Institute of Skin Integrity and Infection Prevention, University of Huddersfield, Huddersfield HD1 3DH, UK * Correspondence: [email protected] Citation: Al-Azzam, S.; Mhaidat, N.M.; Banat, H.A.; Alfaour, M.; Abstract: Coronavirus disease 2019 (COVID-19) has overlapping clinical characteristics with bacterial Ahmad, D.S.; Muller, A.; Al-Nuseirat, respiratory tract infection, leading to the prescription of potentially unnecessary antibiotics. This A.; Lattyak, E.A.; Conway, B.R.; study aimed at measuring changes and patterns of national antimicrobial use for one year preceding Aldeyab, M.A.
    [Show full text]
  • Chapter 12 Antimicrobial Therapy Antibiotics
    Chapter 12 Antimicrobial Therapy Topics: • Ideal drug - Antimicrobial Therapy - Selective Toxicity • Terminology - Survey of Antimicrobial Drug • Antibiotics - Microbial Drug Resistance - Drug and Host Interaction An ideal antimicrobic: Chemotherapy is the use of any chemical - soluble in body fluids, agent in the treatment of disease. - selectively toxic , - nonallergenic, A chemotherapeutic agent or drug is any - reasonable half life (maintained at a chemical agent used in medical practice. constant therapeutic concentration) An antibiotic agent is usually considered to - unlikely to elicit resistance, be a chemical substance made by a - has a long shelf life, microorganism that can inhibit the growth or - reasonably priced. kill microorganisms. There is no ideal antimicrobic An antimicrobic or antimicrobial agent is Selective Toxicity - Drugs that specifically target a chemical substance similar to an microbial processes, and not the human host’s. antibiotic, but may be synthetic. Antibiotics Spectrum of antibiotics and targets • Naturally occurring antimicrobials – Metabolic products of bacteria and fungi – Reduce competition for nutrients and space • Bacteria – Streptomyces, Bacillus, • Molds – Penicillium, Cephalosporium * * 1 The mechanism of action for different 5 General Mechanisms of Action for antimicrobial drug targets in bacterial cells Antibiotics - Inhibition of Cell Wall Synthesis - Disruption of Cell Membrane Function - Inhibition of Protein Synthesis - Inhibition of Nucleic Acid Synthesis - Anti-metabolic activity Antibiotics
    [Show full text]
  • Antiviral Drug Resistance
    Points to Consider: Antiviral Drug Resistance Introduction Development of resistance to antimicrobial agents (including antivirals) is considered to be a natural consequence of rapid replication of microorganisms in the presence of a selective pressure. I.e. it is a natural evolutionary event and should be an expected outcome of the use of antimicrobial agents. The speed with which such resistant organisms develop, and their ability to persist in the population, will be influenced by several factors including the extent to which the antimicrobial agent is used, and the viability of the new (mutated) resistant organism. Microorganisms may also differ naturally in their sensitivity to antimicrobial agents, and the existence of such insensitivity can have an impact on emergence of resistance in two ways. (i) It provides evidence that drug resistant organisms are viable, and could therefore emerge and persist in the population in response to drug use. (ii) Use of antimicrobial agents may create an environment in which pre‐existing insensitive strains may have a selective advantage and spread. Background to drug resistant influenza viruses 1 Adamantanes (amantadine, rimantidine) The existence of viruses resistant or insensitive to this class of antiviral agent is well documented. Many of the currently circulating strains of virus (both human and animal) lack sensitivity to these agents, and clinical use of amantadine or rimantadine has been shown to select for resistant viruses in a high proportion of cases, and within 2‐3 days of starting treatmenti. Such rapid emergence of resistance during treatment may explain the reduced efficacy of rimantidine or amantadine prophylaxis when the index cases were also treatedii.
    [Show full text]
  • Antibiotic Fidaxomicin Is an Rdrp Inhibitor As a Potential New Therapeutic Agent Against Zika Virus
    Yuan et al. BMC Medicine (2020) 18:204 https://doi.org/10.1186/s12916-020-01663-1 RESEARCH ARTICLE Open Access Antibiotic fidaxomicin is an RdRp inhibitor as a potential new therapeutic agent against Zika virus Jie Yuan1,2,3†, Jianchen Yu2,3,4†, Yun Huang3, Zhenjian He2,5, Jia Luo6, Yun Wu2,4,7, Yingchun Zheng8, Jueheng Wu2,4,7, Xun Zhu2,4, Haihe Wang1 and Mengfeng Li2,3,4* Abstract Background: Zika virus (ZIKV) infection is a global health problem, and its complications, including congenital Zika syndrome and Guillain-Barré syndrome, constitute a continued threat to humans. Unfortunately, effective therapeutics against ZIKV infection are not available thus far. Methods: We screened the compounds collection consisting of 1789 FDA-approved drugs by a computational docking method to obtain anti-ZIKV candidate compounds targeting ZIKV RNA-dependent RNA polymerase (RdRp). SPR (BIAcore) assay was employed to demonstrate the candidate compounds’ direct binding to ZIKV RdRp, and polymerase activity assay was used to determine the inhibitory effect on ZIKV RdRp-catalyzed RNA synthesis. The antiviral effects on ZIKV in vitro and in vivo were detected in infected cultured cells and in Ifnar1−/− mice infected by ZIKV virus using plaque assay, western blotting, tissue immunofluorescence, and immunohistochemistry. Results: Here, we report that a first-in-class macrocyclic antibiotic, which has been clinically used to treat Clostridium difficile infection, fidaxomicin, potently inhibits ZIKV replication in vitro and in vivo. Our data showed that fidaxomicin was effective against African and Asian lineage ZIKV in a wide variety of cell lines of various tissue origins, and prominently suppressed ZIKV infection and significantly improved survival of infected mice.
    [Show full text]
  • Design and Evaluation of 5•²-O-Dicarboxylic And
    University of Rhode Island DigitalCommons@URI Open Access Master's Theses 2014 DESIGN AND EVALUATION OF 5′-O-DICARBOXYLIC AND POLYARGININE FATTY ACYL DERIVATIVES OF ANTI-HIV NUCLEOSIDES Bhanu Priya Pemmaraju Venkata University of Rhode Island, [email protected] Follow this and additional works at: https://digitalcommons.uri.edu/theses Recommended Citation Pemmaraju Venkata, Bhanu Priya, "DESIGN AND EVALUATION OF 5′-O-DICARBOXYLIC AND POLYARGININE FATTY ACYL DERIVATIVES OF ANTI-HIV NUCLEOSIDES" (2014). Open Access Master's Theses. Paper 474. https://digitalcommons.uri.edu/theses/474 This Thesis is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Master's Theses by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. DESIGN AND EVALUATION OF 5′-O- DICARBOXYLIC AND POLYARGININE FATTY ACYL DERIVATIVES OF ANTI-HIV NUCLEOSIDES BY BHANU PRIYA, PEMMARAJU VENKATA A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE MASTER’S DEGREE IN BIOMEDICAL AND PHARMACEUTICAL SCIENCES UNIVERSITY OF RHODE ISLAND 2014 MASTER OF SCIENCE THESIS OF BHANU PRIYA, PEMMARAJU VENKATA APPROVED: Thesis Committee: Major Professor Keykavous Parang Roberta King Stephen Kogut Geoffrey D. Bothun Nasser H. Zawia DEAN OF THE GRADUATE SCHOOL UNIVERSITY OF RHODE ISLAND 2014 ABSTRACT 2′,3′-Dideoxynucleoside (ddNs) analogs are the most widely used anti-HIV drugs in the market. Even though these drugs display very potent activities, they have a number of limitations when are used as therapeutic agents. The primary problem associated with ddNs is significant toxicity, such as neuropathy and bone marrow suppression.
    [Show full text]
  • Biochemical Engineering: Ta Da! a Way to Add Fluorine to Natural Products
    RESEARCH HIGHLIGHTS IN BRIEF BIOCHEMICAL ENGINEERING Ta da! A way to add fluorine to natural products Adding fluorine to small molecules can improve their properties, such as preventing enzymatic breakdown and increasing membrane permeation, but it is hard to add fluorine to natural products. Walker et al. engineered polyketide synthase enzymes, which are normally involved in acetate-based biosynthesis, to incorporate fluoroacetate: the primary product of the only biological fluorination route. In Escherichia coli cells, this process was used as a building block to introduce fluorine substituents in a site-selective manner into polyketide-based natural product scaffolds. ORIGINAL RESEARCH PAPER Walker, M. C. et al. Expanding the fluorine chemistry of living systems using engineered polyketide synthase pathways. Science 341, 1089–1094 (2013) INFECTIOUS DISEASE Combating visceral leishmaniasis Visceral leishmaniasis is often fatal, yet current drugs are very toxic and incur resistance. Because Leishmania spp. require exogenous haem for growth, Guha et al. investigated whether haem acquisition could be a potential target. They found that the haemoglobin receptor (HbR) was conserved across several strains of Leishmania, and a HbR-specific antibody was detected in patients with visceral leishmaniasis. Immunization of mice and hamsters with HbR DNA completely protected against virulent Leishmania donovani infection and stimulated the production of protective cytokines as well as CD4+ and CD8+ T cells, which suggests that HbR is a target for vaccine development. ORIGINAL RESEARCH PAPER Guha, R. et al. Vaccination with Leishmania hemoglobin receptor-encoding DNA protects against visceral leishmanias. Sci. Transl. Med. 5, 202ra121 (2013) G PROTEIN-COUPLED RECEPTORS Crystal structures aid ligand mechanistics Two new papers on G protein-coupled receptor (GPCR) structure shed new light on how different ligands interact with their cognate GPCRs.
    [Show full text]
  • A Rational Approach to Identifying Effective Combined Anticoronaviral Therapies Against Feline 2 Coronavirus 3 4 5 S.E
    bioRxiv preprint doi: https://doi.org/10.1101/2020.07.09.195016; this version posted July 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 A rational approach to identifying effective combined anticoronaviral therapies against feline 2 coronavirus 3 4 5 S.E. Cook1*, H. Vogel2, D. Castillo3, M. Olsen4, N. Pedersen5, B. G. Murphy3 6 7 1 Graduate Group Integrative Pathobiology, School of Veterinary Medicine, University of 8 California, Davis, CA, USA 9 10 2School of Veterinary Medicine, University of California, Davis, Ca, USA 11 12 3Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, 13 University of California, Davis, CA, USA 14 15 4Department of Pharmaceutical Sciences, College of Pharmacy-Glendale, Midwestern 16 University, Glendale, AZ, USA 17 18 5Department of Medicine and Epidemiology, School of Veterinary Medicine, University of 19 California, Davis, CA, USA 20 21 22 *Corresponding author 23 24 E-mail: [email protected] (SEC) 25 26 27 Abstract 28 Feline infectious peritonitis (FIP), caused by a genetic mutant of feline enteric coronavirus 29 known as FIPV, is a highly fatal disease of cats with no currently available vaccine or FDA- 30 approved cure. Dissemination of FIPV in affected cats results in a range of clinical signs 31 including cavitary effusions, anorexia, fever and lesions of pyogranulomatous vasculitis and 32 peri-vasculitis with or without central nervous system and/or ocular involvement.
    [Show full text]
  • KALETRA® (Lopinavir/Ritonavir) Capsules (Lopinavir/Ritonavir) Oral Solution
    1 of 57 KALETRA® (lopinavir/ritonavir) capsules (lopinavir/ritonavir) oral solution DESCRIPTION Proprietary name: Kaletra Established name: lopinavir and ritonavir Route of administration: ORAL (C38288) Active ingredients (moiety): Lopinavir (Lopinavir), Ritonavir (Ritonavir) # Strength Form Inactive ingredients 1 133.3 MILLIGRAM, CAPSULE, FD&C Yellow No. 6, gelatin, glycerin, oleic acid, polyoxyl 35 castor oil, 33.3 MILLIGRAM LIQUID FILLED propylene glycol, sorbitol special, titanium dioxide, water (C42954) 2 80 MILLIGRAM, SOLUTION Acesulfame potassium, alcohol, artificial cotton candy flavor, citric acid, 20 MILLIGRAM (C42986) glycerin, high fructose corn syrup, Magnasweet-110 flavor, menthol, natural & artificial vanilla flavor, peppermint oil, polyoxyl 40 hydrogenated castor oil, povidone, propylene glycol, saccharin sodium, sodium chloride, sodium citrate, water KALETRA (lopinavir/ritonavir) is a co-formulation of lopinavir and ritonavir. Lopinavir is an inhibitor of the HIV protease. As co-formulated in KALETRA, ritonavir inhibits the CYP3A- mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir. Lopinavir is chemically designated as [1S-[1R*,(R*), 3R*, 4R*]]-N-[4-[[(2,6- dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro- alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide. Its molecular formula is C37H48N4O5, and its molecular weight is 628.80. Lopinavir has the following structural formula: 2 of 57 Ritonavir is chemically designated as 10-Hydroxy-2-methyl-5-(1-methylethyl)-1- [2-(1- methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-2,4,7,12-tetraazatridecan-13-oic acid, 5-thiazolylmethyl ester, [5S-(5R*,8R*,10R*,11R*)]. Its molecular formula is C37H48N6O5S2, and its molecular weight is 720.95. Ritonavir has the following structural formula: Lopinavir is a white to light tan powder.
    [Show full text]
  • DNA/RNA Synthesis
    DNA/RNA Synthesis RNA synthesis, which is also called DNA transcription, is a highly selective process. Transcription by RNA polymerase II extends beyond RNA synthesis, towards a more active role in mRNA maturation, surveillance and export to the cytoplasm. Single-strand breaks are repaired by DNA ligase using the complementary strand of the double helix as a template, with DNA ligase creating the final phosphodiester bond to fully repair the DNA.DNA ligases discriminate against substrates containing RNA strands or mismatched base pairs at positions near the ends of the nickedDNA. Bleomycin (BLM) exerts its genotoxicity by generating free radicals, whichattack C-4′ in the deoxyribose backbone of DNA, leading to opening of the ribose ring and strand breakage; it is an S-independentradiomimetic agent that causes double-strand breaks in DNA. First strand cDNA is synthesized using random hexamer primers and M-MuLV Reverse Transcriptase (RNase H). Second strand cDNA synthesis is subsequently performed using DNA Polymerase I and RNase H. The remaining overhangs are converted into blunt ends using exonuclease/polymerase activity. After adenylation of the 3′ ends of DNA fragments, NEBNext Adaptor with hairpin loop structure is ligated to prepare the samples for hybridization. Cell cycle and DNA replication are the top two pathways regulated by BET bromodomain inhibition. Cycloheximide blocks the translation of mRNA to protein. www.MedChemExpress.com 1 DNA/RNA Synthesis Inhibitors, Agonists, Activators, Modulators & Chemicals (+)-TK216 (-)-TK216 Cat. No.: HY-122903B Cat. No.: HY-122903A (+)-TK216 is an enantiomer of TK216 (HY-122903). (-)-TK216 is an enantiomer of TK216 (HY-122903). TK216 is an orally active and potent E26 TK216 is an orally active and potent E26 transformation specific (ETS) inhibitor.
    [Show full text]
  • Recent Advances in Antiviral Therapy J Clin Pathol: First Published As 10.1136/Jcp.52.2.89 on 1 February 1999
    J Clin Pathol 1999;52:89–94 89 Recent advances in antiviral therapy J Clin Pathol: first published as 10.1136/jcp.52.2.89 on 1 February 1999. Downloaded from Derek Kinchington Abstract indicated that using a combination of drugs In the early 1980s many institutions in might overcome this problem. The only Britain were seriously considering available drugs during the late 1980s were two whether there was a need for specialist other nucleotide reverse transcriptase inhibi- departments of virology. The arrival of tors (NRTI) which also targeted HIV reverse HIV changed that perception and since transcriptase (HIV-RT): 2',3'-dideoxycytidine then virology and antiviral chemotherapy (ddC) and 2',3'-dideoxyinosine (ddI).56 In have become two very active areas of bio- vitro combination studies gave surprising medical research. Cloning and sequencing results: those viruses that became highly resist- have provided tools to identify viral en- ant to ZDV remained sensitive to both ddC zymes and have brought the day of the and ddI.7 Furthermore, neither cross resistance “designer drug” nearer to reality. At the nor interference between the drugs was an other end of the spectrum of drug discov- issue, and subsequent clinical experience ery, huge numbers of compounds for showed that patients benefited when these two screening can now be generated by combi- compounds were used in combination with natorial chemistry. The impetus to find ZDV.8 It was also found by in vitro studies that drugs eVective against HIV has also virus isolated from patients on long term ZDV stimulated research into novel treatments monotherapy had become insensitive to ZDV, for other virus infections including her- but regained sensitivity when these patients pesvirus, respiratory infections, and were switched to ddI monotherapy.
    [Show full text]
  • Guidelines for the Use of Antiretroviral Agents in Adults and Adolescent Living With
    Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV Developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group of the Office of AIDS Research Advisory Council (OARAC) How to Cite the Adult and Adolescent Guidelines: Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/ AdultandAdolescentGL.pdf. Accessed [insert date] [insert page number, table number, etc. if applicable] It is emphasized that concepts relevant to HIV management evolve rapidly. The Panel has a mechanism to update recommendations on a regular basis, and the most recent information is available on the HIVinfo Web site (http://hivinfo.nih.gov). What’s New in the Guidelines? August 16, 2021 Hepatitis C Virus/HIV Coinfection • Table 18 of this section has been updated to include recommendations regarding concomitant use of fostemsavir or long acting cabotegravir plus rilpivirine with different hepatitis C treatment regimens. June 3, 2021 What to Start • Since the release of the last guidelines, updated data from the Botswana Tsepamo study have shown that the prevalence of neural tube defects (NTD) associated with dolutegravir (DTG) use during conception is much lower than previously reported. Based on these new data, the Panel now recommends that a DTG-based regimen can be prescribed for most people with HIV who are of childbearing potential. Before initiating a DTG-based regimen, clinicians should discuss the risks and benefits of using DTG with persons of childbearing potential, to allow them to make an informed decision.
    [Show full text]